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Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods
are used for early detection of malignancies and postoperative follow-up. Human leukocyte antigen-G (HLA-G) is a nonclassic HLA
class I molecule. Recent studies suggested a relationship between HLA-G positivity and the stage or the phenotype of the malignancy.
In this study, the relationship between serum HLA-G positivity and thyroid cancer was investigated.
Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study. Serum HLA-G levels
were measured using ELISA.
Results: HLA-G was positive in only 3 out of 50 patients with thyroid cancer (2 papillary, 1 follicular type). On the other hand, HLA-G
was positive in 20 out of 45 healthy subjects (P < 0.001). The prevalence of detectable levels of serum HLA-G was independent of sex
and age in the whole study population. No correlation was found between serum HLA-G value and thyroid hormone profile, neither in
papillary thyroid cancer nor follicular thyroid cancer patients.
Conclusion: In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.
Key words: Thyroid cancer, tumor markers, HLA-G, preoperative diagnosis

1. Introduction
The most important surgical indication for a thyroid
nodule is its potential risk of cancer. Though many
diagnostic methods and treatment algorithms have
been developed, it is not always possible to diagnose
thyroid cancers in the preoperative period. The most
commonly used method for preoperative diagnosis
in thyroid cancers is fine-needle aspiration biopsy
(FNAB), which has a range of accuracy of 60%–85%.
Diagnosis by FNAB depends on individual factors.
First of all, it is necessary to take the biopsy directly
from the nodule rather than the neighboring thyroid
tissue. For this reason, biopsies taken in the presence of
ultrasonography are preferred instead of blind biopsies
in many centers. However, if more than one nodule is
present or if the biopsy-intensive radiologist experience
is inadequate, the accuracy of this method is reduced.
Once a biopsy has been taken, it must be evaluated by
an experienced cytologist. Therefore, there is a need for
nonperson-dependent methods to help identify thyroid
cancers preoperatively. For many types of cancer,
immunohistochemical staining methods as well as many
* Correspondence: makin@gazi.edu.tr

markers are used as early signs of a possible cancer or in
the posttreatment period are investigated in serum and
pathology preparations (1)
Human leukocyte antigen-G (HLA-G) is a nonclassic
HLA class I molecule. It is now clear that HLA-G
positivity is associated with the stages of the disease in
breast cancer as in lung cancer, renal cell carcinoma,
and malignant melanoma, also indicating different
expressions among lobular and ductal subtypes (2).
There are insufficient data on the possible role of
serum HLA-G in thyroid cancer patients. In this study,
the relationship between thyroid cancer and serum
HLA-G was investigated.
2. Materials and methods
The study consists of two groups: 50 patients diagnosed
with thyroid cancer and 45 healthy control group subjects.
Serum was obtained from blood samples taken from
both groups and stored at –80 °C for measurement of
the HLA-G level. Patients receiving immunosuppressive
treatment, those detected to have another malignancy,
and those with pregnancy were excluded from the study.
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2.1. Serum HLA-G measurement method
A commercial ELISA kit was used for the measurement
of serum HLA-G (HLA-G ELISA, BioVendor Research
and Diagnostic Products, Czech Republic, Catalog No.
RD194070100R). Following the addition of 100 µL of
serum samples to monoclonal anti-sHLA-G antibodycoated wells, the plate was incubated for 16 hours at 4 °C.
At the end of this period, 100 µL/well conjugate solution
(monoclonal anti-human β2-microglobulin antibody) was
added to wells washed five times in the automated ELISA
washer with the prepared washing solution.
The plate, which was incubated for 1 h at room
temperature, was finally washed five times in the automatic
washer and the substrate was added to make 100 µL/well.
After 25 min of incubation at room temperature and in
darkness, the reaction was stopped by adding stopper
solution (phosphoric acid, 1 M) in such a fashion that it
could create 100 µL/well and optical densities due to color
changes were spectrophotometrically evaluated in an
automated ELISA reader using a 450/620 nm filter.
Microstat, a computer statistical program, was used
to calculate the HLA-G concentrations of the samples.
Taking advantage of the OD values obtained from known
standard concentrations, the OD values of the samples
were subjected to a regression-correlation analysis and the
concentrations in the samples were calculated. The results
were evaluated as HLA-G-positive or HLA-G-negative.
2.2. Statistical analysis
The chi-square test was used for statistical analysis. P <
0.05 was considered as significant.

were matched for age and sex. According to the sixth
TNM staging system, patient distribution was as follows:
28 patients in stage I, 10 in stage II, and 2 in stage III for
papillary thyroid carcinoma (PTC). Nine patients were in
stage I and 1 in stage II for follicular thyroid carcinoma
(FTC).
The HLA-G measurement in 47 out of 50 patients with
thyroid cancer was found to be negative (blue column) by
the ELISA method and positive in three of the cases. On
the other hand, the HLA-G measurement was found to be
negative (blue column) in 25 out of 45 healthy subjects and
positive in 20 by means of ELISA (Figure). Serum HLA-G
positivity was found in lower levels in patients with thyroid
cancer than in healthy subjects (P < 0.001). Among thyroid
carcinoma subtypes, serum HLA-G positivity was seen for
PTC in 2 patients and for FTC in 1 patient. However, the
number of patients was inadequate to obtain significant
statistical data. The prevalence of detectable levels of serum
HLA-G was independent of sex and age in the whole study
population. No correlation was found between serum
HLA-G values and thyroid hormone profiles, neither in
PTC nor FTC patients.
4. Discussion
Thyroid nodules affect approximately 50%–70% of the
adult population. The vast majority of thyroid nodules are
benign. However, thyroid cancer is found in 5%–10% of
the cases, and it is the most common malignant neoplasia
of the endocrine system. PTC and FTC are classified
as differentiated tumors, represent 90% of the cases,
and are derived from follicular cells (3). Early diagnosis
and treatment of thyroid cancer is crucial for improved
prognosis and a better survival rate. The characterization
of new biomarkers has proved useful, not only for the

3. Results
Clinical and histological characteristics of the study
subjects are summarized in the Table. Patients and controls

Table. Clinical and pathological characteristics of patients with PTC and FTC as
well as demographic features of healthy controls
Controls

PTC patients

FTC patients

(n: 47)

(n: 40)

(n: 10)

Age (years)

39 (25–49)

40 (26–51)

41 (33–53)

Sex

33/14

30/10

8/2

Stage I

28

9

Stage II

10

1

(female/male)
TNM

Stage III

2

-

Stage IV

-

-

Age is reported as median (range). TNM, Sixth TNM tumor staging system.
PTC, Papillary thyroid carcinoma. FTC, Follicular thyroid carcinoma.
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Figure. HLA-G positivity in thyroid cancer patients and healthy
subjects.

early detection of thyroid cancer but also for detecting
recurrent and persistent diseases and for predicting the
effectiveness of surgical removal, radioiodine ablation, and
chemotherapy (4).
HLA-G is a nonclassic HLA class I molecule.
Compared to classic HLA class I molecules, it exhibits
less polymorphism and there are seven different isoforms
with 15 different alleles, one of which is null. HLA-G was
initially described as the only HLA molecule expressed in
some trophoblastic cells, but as a result of studies it has
been found that continuous expression is maintained in
the immunosuppressed regions (such as the fetomaternal
junction, thymus, and cornea), and that the soluble forms
are present in amniotic fluid, placental macrophages, cord
blood, and peripheral maternal. To date, it has been shown
in many studies that HLA-G is a molecule that causes
inhibition in a variety of forms (5). In addition, as in
other class I molecules, it has also been shown that when
HLA-G binds to CD8-bearing cells, it induces apoptosis of
CD8+ T cells and NK cells by a Fas-Fas ligand-dependent
mechanism and that if HLA-G expression is present on the
surface of cells targeted by these cells, cytolytic functions
are directly inhibited (6,7). It is thought that the HLA-G
molecule may play a key role in the suppression of the
expected immune response to the fetus by the mother due
to its expression in some trophoblastic cells during the first
defined period. Detection of the sustained expression in
regions protected from the immune system has led to an
emphasis on the immunoinhibitory effect (8).
Recent studies have shown that HLA-G protects
muscle cells from lysis in an autoimmune myopathy model
(9), suggesting a relationship with a higher level of plasma
HLA-G in patients with lung cancer (10). In a study on

liver transplantation, it was shown that liver function
tests were normal in patients with high levels of plasma
HLA-G after transplantation, while the same tests were
impaired in patients with low levels of plasma HLA-G, and
a correlation between these two parameters was shown. It
was also reported that there might be a relationship between
plasma HLA-G levels and tissue rejection (11). Expression
of HLA-G in malignant diseases including hematological
and solid tumors has been extensively investigated,
and its relevance to clinical parameters and potential
significance in diagnosis, prognosis, and immune target
therapy has been postulated (3). Since the first description
of HLA-G expression, its association with malignant
lesions has been intensively studied. There is evidence
that HLA-G is induced in various cancers, including
ovarian, gastric, endometrial, breast, renal cell, and
lung carcinomas; coetaneous melanoma; hematopoietic
tumors; mesothelioma; and trophoblastic tumors. Several
studies have demonstrated a correlation between HLA-G
expression and the patient’s clinical outcome, including
overall survival and the risk of developing metastatic
diseases (4,12–15). However, the data are still conflicting.
To the best of our knowledge, scientific data indicate that
HLA-G can serve as a diagnostic and prognostic tumor
marker, but data about the possible role of HLA-G in
thyroid cancer growth and progression are obscure.
In the literature, there are few publications questioning
the relationship between thyroid diseases and HLA-G
expression. Kemp et al., evaluating autoimmune thyroid
disease, revealed that HLA-G is not expressed in either
thyrocytes or thyroid tissue (16). On the other hand,
Dardano et al. showed significantly higher plasma HLA-G
levels in PTC patients and Hashimoto’s thyroiditis when
compared to healthy individuals (17). Nunes et al. reported
HLA-G expression in 44% of PTC cases, for which the
HLA-G expression was correlated with a higher frequency
of lymph node metastasis. However, the expression of
HLA-G in distinct types of benign and malignant thyroid
tumors is not well known (3,4). In these studies, HLA-G
was highly expressed in thyroid cancer. In our study, on the
contrary, we found it low compared to the control group.
In the mentioned studies (3,4), HLA-G was observed in the
thyroid tissue, while we studied it in the serum. Measuring
HLA-G in the serum with ELISA might not reflect HLA-G
expression in the thyroid tissue. To test this hypothesis,
it would be wise to determine HLA-G presence in both
the serum and the tissue in the same patients. Our results
suggest that measuring serum HLA-G may not be a good
marker for screening for thyroid cancer.
In conclusion, we found low HLA-G levels in the sera
of patients with thyroid cancer, suggesting that measuring
serum HLA G may not be a good marker for screening
for thyroid cancer. Measurement of HLA-G in both serum
and tumor tissue in a larger group of patients with thyroid
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cancer, and conducting subgroup analyses of PTC, FTC,
and anaplastic thyroid patients, may probably give more
accurate information. The lack of evaluation of HLA-G
protein expression in both normal thyroid and cancer
tissue was the major drawback of our study. The integrated
use of serum HLA-G measurement and HLA-G tissue

expression might contribute to a better understanding of
the actual role of the HLA-G complex in thyroid tumor
growth and progression. Moreover, prospective studies
are necessary to confirm the actual role and clinical
relevance of the HLA-G complex in the development and
progression of thyroid cancers.
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